Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q3 2015 · 10-Q
Revenue$470.00M$470.00M−11.4% vs Q3 2014 Net Income$17.40M$17.40M+51.3% vs Q3 2014 EPS Diluted$0.59$0.59+51.3% vs Q3 2014 Gross Profit$263,500,000−8.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flowderived$82,279,000−9.2% Free Cash Flowderived$57,535,000−9.1% Margins · derivedGross margin56.1%+1.7 pt vs Q3 2014
Operating margin7.0%+0.7 pt vs Q3 2014
Net margin3.7%+1.5 pt vs Q3 2014
ended Sep 30, 2015 · filed Nov 5, 2015 · 36 d after period end